16:03 EDT Vanda Pharmaceuticals (VNDA) sees FY25 revenue $210M-$250M, consensus $224.84M
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals Advances with Promising Social Anxiety Disorder Treatment Study
- Vanda Pharmaceuticals Advances Dry Eye Treatment with VSJ-110 Study
- Vanda Pharmaceuticals Completes Key Bioequivalence Study for Schizophrenia and Bipolar Disorder Treatment
- VNDA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Vanda’s FDA Agreement Boosts Buy Rating with Expedited Drug Reviews